Drugs Market Research Reports & Industry Analysis

The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.

Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.

A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.

Publications found: 8,499

Sort by:

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Drugs in Development, 2021

US$ 3,000.00

Potassium Voltage Gated Channel Subfamily A Member 3 (Voltage Gated Potassium Channel Subunit Kv1.3 or KCNA3) - Drugs in Development, 2021 SUMMARY Potassium Voltage Gated Channel Subfamily A Member 3...

April 2021 40 pages

Potassium Voltage Gated Channel Subfamily H Member 2 (HERG or Voltage Gated Potassium Channel Subunit Kv11.1 or Eag Homolog or KCNH2) - Drugs in Development, 2021

US$ 3,000.00

Potassium Voltage Gated Channel Subfamily H Member 2 (HERG or Voltage Gated Potassium Channel Subunit Kv11.1 or Eag Homolog or KCNH2) - Drugs in Development, 2021 SUMMARY Potassium Voltage Gated Chann...

April 2021 35 pages

Pouchitis (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Pouchitis (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Pouchitis (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Pouchitis pipeline landscape. The report provide...

April 2021 35 pages

Pre-Eclampsia (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Pre-Eclampsia (Cardiovascular) - Drugs in Development, 2021 SUMMARY Pre-Eclampsia (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Pre-Eclampsia pipeline landscape. The report...

April 2021 35 pages

Premature Ovarian Failure (Women's Health) - Drugs in Development, 2021

US$ 2,000.00

Premature Ovarian Failure (Women's Health) - Drugs in Development, 2021 SUMMARY Premature Ovarian Failure (Women's Health) - Drugs in Development, 2021 provides an overview of the Premature Ovarian Fa...

April 2021 30 pages

Primary Ciliary Dyskinesia (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Primary Ciliary Dyskinesia (Respiratory) - Drugs in Development, 2021 SUMMARY Primary Ciliary Dyskinesia (Respiratory) - Drugs in Development, 2021 provides an overview of the Primary Ciliary Dyskines...

April 2021 35 pages

Primary CNS Lymphoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Primary CNS Lymphoma (Oncology) - Drugs in Development, 2021 SUMMARY Primary CNS Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Primary CNS Lymphoma pipeline landscape. T...

April 2021 50 pages

Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021

US$ 2,000.00

Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021 SUMMARY Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021 provides...

April 2021 30 pages

Primary Hyperoxaluria Type I (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021

US$ 2,000.00

Primary Hyperoxaluria Type I (Genito Urinary System And Sex Hormones) - Drugs in Development, 2021 SUMMARY Primary Hyperoxaluria Type I (Genito Urinary System And Sex Hormones) - Drugs in Development,...

April 2021 30 pages

Primary Mediastinal B-Cell Lymphoma (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Primary Mediastinal B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 SUMMARY Primary Mediastinal B-Cell Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Primary Medi...

April 2021 130 pages

Primary Progressive Multiple Sclerosis (PPMS) (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Primary Progressive Multiple Sclerosis (PPMS) (Central Nervous System) - Drugs in Development, 2021 SUMMARY Primary Progressive Multiple Sclerosis (PPMS) (Central Nervous System) - Drugs in Developmen...

April 2021 55 pages

Primitive Neuroectodermal Tumor (PNET) (Oncology) - Drugs in Development, 2021

US$ 2,000.00

Primitive Neuroectodermal Tumor (PNET) (Oncology) - Drugs in Development, 2021 SUMMARY Primitive Neuroectodermal Tumor (PNET) (Oncology) - Drugs in Development, 2021 provides an overview of the Primit...

April 2021 40 pages

Proctitis (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Proctitis (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Proctitis (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Proctitis pipeline landscape. The report provide...

April 2021 35 pages

Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR) - Drugs in Development, 2021

US$ 3,000.00

Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3 or PGR) - Drugs in Development, 2021 SUMMARY Progesterone Receptor (Nuclear Receptor Subfamily 3 Group C Member 3 or NR3C3...

April 2021 95 pages

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drugs in Development, 2021

US$ 3,500.00

Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drugs in Development, 2021 SUMMARY Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drugs in Development, 2021 pr...

April 2021 300 pages

Programmed Cell Death 1 Ligand 2 (Butyrophilin B7 DC or CD273 or PDCD1LG2) - Drugs in Development, 2021

US$ 3,000.00

Programmed Cell Death 1 Ligand 2 (Butyrophilin B7 DC or CD273 or PDCD1LG2) - Drugs in Development, 2021 SUMMARY Programmed Cell Death 1 Ligand 2 (Butyrophilin B7 DC or CD273 or PDCD1LG2) - Drugs in De...

April 2021 35 pages

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drugs in Development, 2021

US$ 3,500.00

Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drugs in Development, 2021 SUMMARY Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Drugs in Development, 2021 provides in depth anal...

April 2021 270 pages

Progressive Familial Intrahepatic Cholestasis (Gastrointestinal) - Drugs in Development, 2021

US$ 2,000.00

Progressive Familial Intrahepatic Cholestasis (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Progressive Familial Intrahepatic Cholestasis (Gastrointestinal) - Drugs in Development, 2021 prov...

April 2021 35 pages

Prolow Density Lipoprotein Receptor Related Protein 1 (Alpha 2 Macroglobulin Receptor or Apolipoprotein E Receptor or CD91 or LRP1) - Drugs in Development, 2021

US$ 3,000.00

Prolow Density Lipoprotein Receptor Related Protein 1 (Alpha 2 Macroglobulin Receptor or Apolipoprotein E Receptor or CD91 or LRP1) - Drugs in Development, 2021 SUMMARY Prolow Density Lipoprotein Rece...

April 2021 30 pages

Prolyl Endopeptidase (Post Proline Cleaving Enzyme or PREP or EC 3.4.21.26) - Drugs in Development, 2021

US$ 3,000.00

Prolyl Endopeptidase (Post Proline Cleaving Enzyme or PREP or EC 3.4.21.26) - Drugs in Development, 2021 SUMMARY Prolyl Endopeptidase (Post Proline Cleaving Enzyme or PREP or EC 3.4.21.26) - Drugs in...

April 2021 30 pages

Propionic Acidemia (Metabolic Disorders) - Drugs in Development, 2021

US$ 2,000.00

Propionic Acidemia (Metabolic Disorders) - Drugs in Development, 2021 SUMMARY Propionic Acidemia (Metabolic Disorders) - Drugs in Development, 2021 provides an overview of the Propionic Acidemia pipel...

April 2021 35 pages

Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR) - Drugs in Development, 2021

US$ 3,000.00

Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or PTGIR) - Drugs in Development, 2021 SUMMARY Prostacyclin Receptor (Prostaglandin I2 Receptor or Prostanoid IP Receptor or...

April 2021 55 pages

Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1) - Drugs in Development, 2021

US$ 3,000.00

Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1) - Drugs in Development, 2021 SUMMARY Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1) - Drugs in Deve...

April 2021 50 pages

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Drugs in Development, 2021

US$ 3,000.00

Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Drugs in Development, 2021 SUMMARY Prostaglandin E2 Receptor EP2 Subtype (Prostanoid EP2 Receptor or PTGER2) - Drugs in Deve...

April 2021 35 pages

Prostaglandin F2 Alpha Receptor (Prostanoid FP Receptor or PTGFR) - Drugs in Development, 2021

US$ 3,000.00

Prostaglandin F2 Alpha Receptor (Prostanoid FP Receptor or PTGFR) - Drugs in Development, 2021 SUMMARY Prostaglandin F2 Alpha Receptor (Prostanoid FP Receptor or PTGFR) - Drugs in Development, 2021 pr...

April 2021 60 pages

Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1) - Drugs in Development, 2021

US$ 3,000.00

Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1) - Drugs in Development, 2021 SUMMARY Prostaglan...

April 2021 160 pages

Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1) - Drugs in Development, 2021

US$ 3,500.00

Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1) - Drugs in Development, 2021 SUMMARY...

April 2021 230 pages

Prostaglandin G/H Synthase (Cyclooxygenase or COX or PTGS or EC 1.14.99.1) - Drugs in Development, 2021

US$ 3,000.00

Prostaglandin G/H Synthase (Cyclooxygenase or COX or PTGS or EC 1.14.99.1) - Drugs in Development, 2021 SUMMARY Prostaglandin G/H Synthase (Cyclooxygenase or COX or PTGS or EC 1.14.99.1) - Drugs in De...

April 2021 45 pages

Protein Cysteine N Palmitoyltransferase Porcupine (Protein MG61 or PORCN or EC 2.3.1.) - Drugs in Development, 2021

US$ 3,000.00

Protein Cysteine N Palmitoyltransferase Porcupine (Protein MG61 or PORCN or EC 2.3.1.) - Drugs in Development, 2021 SUMMARY Protein Cysteine N Palmitoyltransferase Porcupine (Protein MG61 or PORCN or...

April 2021 30 pages

Protein Disulfide Isomerase (Prolyl 4 Hydroxylase Subunit Beta or Cellular Thyroid Hormone Binding Protein or p55 or P4HB or EC 5.3.4.1) - Drugs in Development, 2021

US$ 3,000.00

Protein Disulfide Isomerase (Prolyl 4 Hydroxylase Subunit Beta or Cellular Thyroid Hormone Binding Protein or p55 or P4HB or EC 5.3.4.1) - Drugs in Development, 2021 SUMMARY Protein Disulfide Isomeras...

April 2021 30 pages

Protein Kinase B (PKB or AKT or EC 2.7.11.1) - Drugs in Development, 2021

US$ 3,000.00

Protein Kinase B (PKB or AKT or EC 2.7.11.1) - Drugs in Development, 2021 SUMMARY Protein Kinase B (PKB or AKT or EC 2.7.11.1) - Drugs in Development, 2021 provides in depth analysis on Protein Kinase...

April 2021 60 pages

Protein Kinase C Delta Type (Tyrosine Protein Kinase PRKCD or nPKC Delta or PRKCD or EC 2.7.11.13 or EC 2.7.10.2) - Drugs in Development, 2021

US$ 3,000.00

Protein Kinase C Delta Type (Tyrosine Protein Kinase PRKCD or nPKC Delta or PRKCD or EC 2.7.11.13 or EC 2.7.10.2) - Drugs in Development, 2021 SUMMARY Protein Kinase C Delta Type (Tyrosine Protein Kin...

April 2021 35 pages

Protein Kinase C (PKC or PRKC or EC 2.7.11.13) - Drugs in Development, 2021

US$ 3,000.00

Protein Kinase C (PKC or PRKC or EC 2.7.11.13) - Drugs in Development, 2021 SUMMARY Protein Kinase C (PKC or PRKC or EC 2.7.11.13) - Drugs in Development, 2021 provides in depth analysis on Protein Ki...

April 2021 45 pages

Protein Tyrosine Phosphatase (EC 3.1.3.48) - Drugs in Development, 2021

US$ 3,000.00

Protein Tyrosine Phosphatase (EC 3.1.3.48) - Drugs in Development, 2021 SUMMARY Protein Tyrosine Phosphatase (EC 3.1.3.48) - Drugs in Development, 2021 provides in depth analysis on Protein Tyrosine P...

April 2021 30 pages

Proteinase Activated Receptor 1 (PAR1 or Coagulation Factor II Receptor or Thrombin Receptor or F2R) - Drugs in Development, 2021

US$ 3,000.00

Proteinase Activated Receptor 1 (PAR1 or Coagulation Factor II Receptor or Thrombin Receptor or F2R) - Drugs in Development, 2021 SUMMARY Proteinase Activated Receptor 1 (PAR1 or Coagulation Factor II...

April 2021 35 pages

Prothrombin (Coagulation Factor II or F2 or EC 3.4.21.5) - Drugs in Development, 2021

US$ 3,000.00

Prothrombin (Coagulation Factor II or F2 or EC 3.4.21.5) - Drugs in Development, 2021 SUMMARY Prothrombin (Coagulation Factor II or F2 or EC 3.4.21.5) - Drugs in Development, 2021 provides in depth an...

April 2021 50 pages

Proto Oncogene Mas (MAS1) - Drugs in Development, 2021

US$ 3,000.00

Proto Oncogene Mas (MAS1) - Drugs in Development, 2021 SUMMARY Proto Oncogene Mas (MAS1) - Drugs in Development, 2021 provides in depth analysis on Proto Oncogene Mas (MAS1) targeted pipeline therapeu...

April 2021 35 pages

Protozoal Infection (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Protozoal Infection (Infectious Disease) - Drugs in Development, 2021 SUMMARY Protozoal Infection (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Protozoal Infection pipe...

April 2021 30 pages

Prurigo (Dermatology) - Drugs in Development, 2021

US$ 2,000.00

Prurigo (Dermatology) - Drugs in Development, 2021 SUMMARY Prurigo (Dermatology) - Drugs in Development, 2021 provides an overview of the Prurigo pipeline landscape. The report provides comprehensive...

April 2021 35 pages

Pseudomonas Aeruginosa Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,500.00

Pseudomonas Aeruginosa Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Pseudomonas Aeruginosa Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of...

April 2021 220 pages

Pseudomonas Infections (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Pseudomonas Infections (Infectious Disease) - Drugs in Development, 2021 SUMMARY Pseudomonas Infections (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Pseudomonas Infect...

April 2021 35 pages

Psychiatric Disorders (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Psychiatric Disorders (Central Nervous System) - Drugs in Development, 2021 SUMMARY Psychiatric Disorders (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Psychiatric...

April 2021 125 pages

Psychosis (Central Nervous System) - Drugs in Development, 2021

US$ 2,000.00

Psychosis (Central Nervous System) - Drugs in Development, 2021 SUMMARY Psychosis (Central Nervous System) - Drugs in Development, 2021 provides an overview of the Psychosis pipeline landscape. The re...

April 2021 70 pages

Pulmonary Fibrosis (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Pulmonary Fibrosis (Respiratory) - Drugs in Development, 2021 SUMMARY Pulmonary Fibrosis (Respiratory) - Drugs in Development, 2021 provides an overview of the Pulmonary Fibrosis pipeline landscape. T...

April 2021 95 pages

Pulmonary Hypertension (Cardiovascular) - Drugs in Development, 2021

US$ 2,000.00

Pulmonary Hypertension (Cardiovascular) - Drugs in Development, 2021 SUMMARY Pulmonary Hypertension (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Pulmonary Hypertension pip...

April 2021 65 pages

Pulmonary Inflammation (Respiratory) - Drugs in Development, 2021

US$ 2,000.00

Pulmonary Inflammation (Respiratory) - Drugs in Development, 2021 SUMMARY Pulmonary Inflammation (Respiratory) - Drugs in Development, 2021 provides an overview of the Pulmonary Inflammation pipeline...

April 2021 50 pages

Pulmonary Radiation Toxicity (Toxicology) - Drugs in Development, 2021

US$ 2,000.00

Pulmonary Radiation Toxicity (Toxicology) - Drugs in Development, 2021 SUMMARY Pulmonary Radiation Toxicity (Toxicology) - Drugs in Development, 2021 provides an overview of the Pulmonary Radiation To...

April 2021 35 pages

Pulmonary Tuberculosis (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Pulmonary Tuberculosis (Infectious Disease) - Drugs in Development, 2021 SUMMARY Pulmonary Tuberculosis (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Pulmonary Tubercul...

April 2021 50 pages

Q Fever (Infectious Disease) - Drugs in Development, 2021

US$ 2,000.00

Q Fever (Infectious Disease) - Drugs in Development, 2021 SUMMARY Q Fever (Infectious Disease) - Drugs in Development, 2021 provides an overview of the Q Fever pipeline landscape. The report provides...

April 2021 30 pages

Rab Proteins Geranylgeranyltransferase Component A 1 (Choroideremia Protein or Rab Escort Protein 1 or TCD Protein or CHM) - Drugs in Development, 2021

US$ 3,000.00

Rab Proteins Geranylgeranyltransferase Component A 1 (Choroideremia Protein or Rab Escort Protein 1 or TCD Protein or CHM) - Drugs in Development, 2021 SUMMARY Rab Proteins Geranylgeranyltransferase C...

April 2021 30 pages

Filters

Clear all